ALVOAlvotech

$4.91

$3.0052 weeks$9.00

Price

$4.91-42%1Y

1M+55%1Y-42%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

4/10

Value68

Quality40

Momentum24

Growth18

Strongest Value, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Our mission is to improve the health and quality of life of patients around the world by broadening the availability and accessibility of proven treatments for various diseases.

In the company’s own words · 20-F filed Mar 31, 2026 · SEC EDGAR

P/E (TTM)49.1

Market Cap$1.22B

1Y Return-42%

5Y Return-

Alvotech (ALVO) reported revenue of $280M in H2 2025 (quarter ended December 31, 2025), up 294% from the same quarter a year earlier. That came with a gross margin of 66% and net loss of $114M. For the full year FY2025, revenue was $586M (+20% year on year) and net income $28M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - Specialty & Generic

Ranks #27 of 28 by Smart Score

Compare peers

COLL-2.1%

Collegium Pharmaceutical, Inc.

XERS0.00%

Xeris Biopharma Holdings, Inc.

PAHC+1.5%

Phibro Animal Health Corporation